Elizabeth M Burnette1,2, Lara A Ray1,3, Michael R Irwin1,3,4,5, Erica N Grodin1. 1. Department of Psychology, University of California at Los Angeles, Los Angeles, California, USA. 2. Neuroscience Interdepartmental Program, University of California at Los Angeles, Los Angeles, California, USA. 3. Department of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, California, USA. 4. Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California at Los Angeles, Los Angeles, California, USA. 5. Cousins Center for Psychoneuroimmunology, University of California at Los Angeles, Los Angeles, California, USA.
Abstract
BACKGROUND: Ibudilast, a novel neuroimmune modulator being studied to treat alcohol use disorder (AUD), was shown in a randomized controlled trial (NCT03489850) to reduce ventral striatum (VS) activation in response to visual alcohol cues. The present study extended this finding by probing the effects of ibudilast on alcohol cue-elicited functional connectivity (i.e., temporally correlated activation) with the VS seed. The study also tests the association between functional connectivity and alcohol use during the trial. METHODS: Non-treatment-seeking participants (n = 45) with current alcohol use disorder were randomized to receive twice-daily dosing with either ibudilast (50 mg; n = 20) or placebo (n = 25). Upon reaching the target dosagee of the medication or placebo, participants completed a functional neuroimaging alcohol cue reactivity paradigm. Drinks per drinking day were assessed at baseline and daily during the 2-week trial. RESULTS: Ibudilast reduced alcohol cue-elicited functional connectivity between the VS seed and reward-processing regions including the orbitofrontal and anterior cingulate cortices compared with placebo (p < 0.05). Cue-elicited functional connectivity was correlated with drinks per drinking day (R2 = 0.5351, p < 0.001), and ibudilast reduced this association in similar reward-processing regions compared with placebo. CONCLUSIONS: Ibudilast's effects on drinking outcomes may be related to the attenuation of functional connectivity in frontostriatal circuits related to reward processing. These results provide an important proof of concept for this novel pharmacotherapy and support the clinical utility of incorporating neuroimaging-and especially functional connectivity-analyses into medication development.
BACKGROUND: Ibudilast, a novel neuroimmune modulator being studied to treat alcohol use disorder (AUD), was shown in a randomized controlled trial (NCT03489850) to reduce ventral striatum (VS) activation in response to visual alcohol cues. The present study extended this finding by probing the effects of ibudilast on alcohol cue-elicited functional connectivity (i.e., temporally correlated activation) with the VS seed. The study also tests the association between functional connectivity and alcohol use during the trial. METHODS: Non-treatment-seeking participants (n = 45) with current alcohol use disorder were randomized to receive twice-daily dosing with either ibudilast (50 mg; n = 20) or placebo (n = 25). Upon reaching the target dosagee of the medication or placebo, participants completed a functional neuroimaging alcohol cue reactivity paradigm. Drinks per drinking day were assessed at baseline and daily during the 2-week trial. RESULTS: Ibudilast reduced alcohol cue-elicited functional connectivity between the VS seed and reward-processing regions including the orbitofrontal and anterior cingulate cortices compared with placebo (p < 0.05). Cue-elicited functional connectivity was correlated with drinks per drinking day (R2 = 0.5351, p < 0.001), and ibudilast reduced this association in similar reward-processing regions compared with placebo. CONCLUSIONS: Ibudilast's effects on drinking outcomes may be related to the attenuation of functional connectivity in frontostriatal circuits related to reward processing. These results provide an important proof of concept for this novel pharmacotherapy and support the clinical utility of incorporating neuroimaging-and especially functional connectivity-analyses into medication development.
Authors: Mark A Frye; David J Hinton; Victor M Karpyak; Joanna M Biernacka; Lee J Gunderson; Scott E Feeder; Doo-Sup Choi; John D Port Journal: J Clin Psychopharmacol Date: 2016-12 Impact factor: 3.153
Authors: Lara A Ray; Spencer Bujarski; Steve Shoptaw; Daniel Jo Roche; Keith Heinzerling; Karen Miotto Journal: Neuropsychopharmacology Date: 2017-01-16 Impact factor: 8.294
Authors: Aaron C Lim; Dara G Ghahremani; Erica N Grodin; ReJoyce Green; Spencer Bujarski; Emily E Hartwell; Kelly E Courtney; Kent Hutchison; Karen Miotto; Lara A Ray Journal: Drug Alcohol Depend Date: 2019-05-09 Impact factor: 4.852
Authors: Jill X O'Reilly; Mark W Woolrich; Timothy E J Behrens; Stephen M Smith; Heidi Johansen-Berg Journal: Soc Cogn Affect Neurosci Date: 2012-05-07 Impact factor: 3.436
Authors: Elizabeth M Burnette; Steven J Nieto; Erica N Grodin; Lindsay R Meredith; Brian Hurley; Karen Miotto; Artha J Gillis; Lara A Ray Journal: Drugs Date: 2022-02-08 Impact factor: 9.546